Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD.

Autor: Knikman JE; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Zhai Q; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands., Lunenburg CATC; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Henricks LM; Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, The Netherlands., Böhringer S; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands., van der Lee M; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands., de Man FM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands., Offer SM; Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.; Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, USA., Shrestha S; Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Creemers GJ; Department of Medical Oncology, Catharina Hospital, Eindhoven, The Netherlands., Baars A; Department of Internal Medicine, Hospital Gelderse Vallei, Ede, The Netherlands., Dezentjé VO; Department of Internal Medicine, Reinier de Graaf Hospital, Delft, The Netherlands.; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Imholz ALT; Department of Internal Medicine, Deventer Hospital, Deventer, The Netherlands., Jeurissen FJF; Department of Internal Medicine, Haaglanden Medical Center, The Hague, The Netherlands., Portielje JEA; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Jansen RLH; Department of Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands., Hamberg P; Department of Internal Medicine, Franciscus Gasthuis en Vlietland, Rotterdam, The Netherlands., Droogendijk HJ; Department of Internal Medicine, Bravis Hospital, Roosendaal, The Netherlands., Koopman M; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Nieboer P; Department of Internal Medicine, Wilhelmina Hospital Assen, Assen, The Netherlands., van de Poel MHW; Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands., Mandigers CMPW; Department of Internal Medicine, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands., van Schaik RHN; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands., Schellens JHM; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands., Cats A; Department of Gastroenterology and Hepatology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Guchelaar HJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands. h.j.guchelaar@lumc.nl., Swen JJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.

Publikováno v: Genome medicine [Genome Med] 2024 Aug 15; Vol. 16 (1), pp. 101. Date of Electronic Publication: 2024 Aug 15.

Phase I study of intraperitoneal irinotecan combined with palliative systemic chemotherapy in patients with colorectal peritoneal metastases.

Autor: van Eerden RAG; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., de Boer NL; Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., van Kooten JP; Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Bakkers C; Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands., Dietz MV; Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Creemers GM; Department of Medical Oncology, Catharina Cancer Institute, Eindhoven, the Netherlands., Buijs SM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Bax R; Department of Medical Oncology, Catharina Cancer Institute, Eindhoven, the Netherlands., de Man FM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Lurvink RJ; Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands., Diepeveen M; Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Brandt-Kerkhof ARM; Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., van Meerten E; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Koolen SLW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.; Department of Hospital Pharmacy, Erasmus MC, Rotterdam, the Netherlands., de Hingh IHJT; Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands., Verhoef C; Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Burger JWA; Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands.

Publikováno v: The British journal of surgery [Br J Surg] 2023 Oct 10; Vol. 110 (11), pp. 1502-1510.

DPYD*7 as a Predictor of Severe Fluoropyrimidine-Related Adverse Events.

Autor: de With M; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands.; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands., Brufau G; Department of Clinical Chemistry and Haematology, Albert Schweitzer Hospital, Dordrecht, the Netherlands., van den Berg LA; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands., de Man FM; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands., Trajkovic M; Department of Medical Oncology, Albert Schweitzer Hospital, Dordrecht, the Netherlands., Thijs MF; Department of Medical Oncology, Ikazia Hospital, Rotterdam, the Netherlands., Castel R; Department of Clinical Chemistry and Haematology, Albert Schweitzer Hospital, Dordrecht, the Netherlands.; Medical Laboratory Ikazia, Ikazia Hospital, Rotterdam, the Netherlands., Vermeer HJ; Department of Clinical Chemistry and Haematology, Albert Schweitzer Hospital, Dordrecht, the Netherlands., El Bouazzaoui S; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands., van Hemel A; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands., Matic M; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands., Bins S; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands., van Schaik RHN; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands.

Publikováno v: JCO precision oncology [JCO Precis Oncol] 2022 Jul; Vol. 6, pp. e2200180.

Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover Trial.

Autor: van Doorn L; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Heersche N; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., de Man FM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., de Bruijn P; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Bijl I; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Oomen-de Hoop E; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Eskens FALM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., van der Gaast A; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Bins S; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2022 Feb; Vol. 111 (2), pp. 455-460. Date of Electronic Publication: 2021 Oct 31.

Effects of Protein and Calorie Restriction on the Metabolism and Toxicity Profile of Irinotecan in Cancer Patients.

Autor: de Man FM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., van Eerden RAG; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., van Doorn GM; Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands., Oomen-de Hoop E; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Koolen SLW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.; Department of Hospital Pharmacy, Erasmus MC, University Medical Center, Rotterdam, The Netherlands., Olieman JF; Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands., de Bruijn P; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Veraart JN; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., van Halteren HK; Department of Internal Medicine, Admiraal de Ruyter Hospital, Goes, The Netherlands., Sandberg Y; Department of Internal Medicine, Maasstad Hospital, Rotterdam, The Netherlands., Moelker A; Department of Radiology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands., IJzermans JNM; Department of Surgery, Erasmus MC, University Medical Center, Rotterdam, The Netherlands., Lolkema MP; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., van Gelder T; Department of Hospital Pharmacy, Erasmus MC, University Medical Center, Rotterdam, The Netherlands., Dollé MET; Centre for Health Protection Research, National Institute for Public Health and Environment (RIVM), Bilthoven, The Netherlands., de Bruin RWF; Department of Surgery, Erasmus MC, University Medical Center, Rotterdam, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 May; Vol. 109 (5), pp. 1304-1313. Date of Electronic Publication: 2020 Dec 06.